Pricing Log in Create free account

Aktis Oncology, Inc. (AKTS) vs Corvus Pharmaceuticals, Inc. (CRVS)

Aktis Oncology, Inc. and Corvus Pharmaceuticals, Inc. are both Biotechnology companies. Aktis Oncology, Inc. and Corvus Pharmaceuticals, Inc. are of similar size ($826.0M and $818.5M). Corvus Pharmaceuticals, Inc. has the higher net margin (0.00% vs −782.0%) and the lower return on invested capital (−352.5% vs 0.00%). Across the 13 metrics below, Corvus Pharmaceuticals, Inc. leads on 7 and Aktis Oncology, Inc. on 6.

Valuation

Metric AKTS CRVS Biotechnology median
P/E n/m n/m 10.60
P/S 90.34 n/m 9.40
P/B 1.80 4.33 2.13
Price to free cash flow n/m n/m 25.18
EV/EBITDA n/m n/m 0.66
EV/Sales 36.79 n/m 9.02
Earnings yield (264.93%) (5.77%) (32.88%)
Free cash flow yield (15.97%) (4.63%) (23.13%)

Profitability

Metric AKTS CRVS Biotechnology median
Gross margin 100.00% 0.00% 68.51%
Operating margin (939.13%) 0.00% 0.00%
Net margin (781.95%) 0.00% 0.00%
Free cash flow margin (1,442.91%) 0.00% 0.00%
Return on equity (34.45%) (35.43%) (51.96%)
Return on assets (22.22%) (32.93%) (46.06%)
Return on invested capital 0.00% (352.49%) 0.00%

Growth

Metric AKTS CRVS Biotechnology median
Revenue growth (TTM) — — 6.76%
EPS growth (last fiscal year) (25.43%) 48.04% 29.88%
Revenue growth, 5-year CAGR — — 9.75%
Net income growth, 5-year CAGR — 0.00% 0.00%

Health

Metric AKTS CRVS Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 16.33 16.16 4.97
Net debt to EBITDA 2.95 1.28 1.01

Dividend

Metric AKTS CRVS Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric AKTS CRVS Biotechnology median
Market cap 825.95m 818.50m 161.82m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack